9.31
price down icon6.43%   -0.64
after-market After Hours: 9.31
loading
Dyne Therapeutics Inc stock is traded at $9.31, with a volume of 2.22M. It is down -6.43% in the last 24 hours and down -2.72% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$9.95
Open:
$9.97
24h Volume:
2.22M
Relative Volume:
0.79
Market Cap:
$1.06B
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-2.6152
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
+1.53%
1M Performance:
-2.72%
6M Performance:
-30.83%
1Y Performance:
-79.09%
1-Day Range:
Value
$9.25
$9.97
1-Week Range:
Value
$9.00
$10.23
52-Week Range:
Value
$6.36
$47.45

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name
Name
Dyne Therapeutics Inc
Name
Phone
(781) 786-8230
Name
Address
1560 TRAPELO ROAD, WALTHAM
Name
Employee
192
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
DYN's Discussions on Twitter

Compare DYN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
DYN
Dyne Therapeutics Inc
9.31 1.41B 0 -294.51M -244.42M -3.56
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
460.83 120.60B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.63 60.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.79 42.87B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
595.19 36.23B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.51 31.54B 3.81B -644.79M -669.77M -6.24

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-24-25 Initiated Bernstein Mkt Perform
Jun-11-25 Resumed Raymond James Outperform
Jun-02-25 Resumed Oppenheimer Outperform
May-29-25 Initiated Evercore ISI Outperform
Mar-12-25 Initiated BMO Capital Markets Outperform
Mar-07-25 Initiated Scotiabank Sector Outperform
Dec-13-24 Initiated Robert W. Baird Outperform
Nov-26-24 Initiated RBC Capital Mkts Outperform
Oct-24-24 Downgrade JP Morgan Overweight → Neutral
May-21-24 Reiterated Chardan Capital Markets Buy
Apr-30-24 Initiated Morgan Stanley Overweight
Feb-20-24 Initiated H.C. Wainwright Buy
Feb-27-23 Upgrade Raymond James Outperform → Strong Buy
Feb-15-23 Initiated Oppenheimer Outperform
Jan-26-23 Initiated Guggenheim Buy
Jul-20-22 Initiated Chardan Capital Markets Buy
Jul-12-22 Initiated Raymond James Outperform
Oct-12-20 Initiated JP Morgan Overweight
Oct-12-20 Initiated Jefferies Buy
Oct-12-20 Initiated Piper Sandler Overweight
Oct-12-20 Initiated Stifel Buy
View All

Dyne Therapeutics Inc Stock (DYN) Latest News

pulisher
07:00 AM

Dyne Therapeutics Narrowed Its Loss And Won Analyst Support - Finimize

07:00 AM
pulisher
05:02 AM

Dyne Therapeutics extends cash runway as it advances key drug programs - Investing.com Australia

05:02 AM
pulisher
04:43 AM

Dyne Therapeutics, Inc. Q2 Loss Increases, Misses Estimates - Nasdaq

04:43 AM
pulisher
04:32 AM

Dyne (DYN) Expects Funding to Sustain Operations Through 2027 - GuruFocus

04:32 AM
pulisher
04:32 AM

Dyne (DYN) Advances Clinical Programs and Strengthens Financial Position - GuruFocus

04:32 AM
pulisher
04:24 AM

Dyne Therapeutics Extends Cash Runway to Q3 2027, Advances Clinical Trials for DM1 and DMD - Quiver Quantitative

04:24 AM
pulisher
04:16 AM

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus

04:16 AM
pulisher
04:11 AM

Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire

04:11 AM
pulisher
06:38 AM

What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockDiscover breakthrough investment opportunities - jammulinksnews.com

06:38 AM
pulisher
02:33 AM

Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionUnlock exclusive trading strategies for gains - jammulinksnews.com

02:33 AM
pulisher
02:32 AM

How many analysts rate Dyne Therapeutics Inc. as a “Buy”Exceptional market positioning - jammulinksnews.com

02:32 AM
pulisher
12:27 PM

What is Dyne Therapeutics Inc. company’s growth strategyDiscover market opportunities with expert help - jammulinksnews.com

12:27 PM
pulisher
Jul 27, 2025

Should I hold or sell Dyne Therapeutics Inc. stock in 2025Breakthrough investment results - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What makes Dyne Therapeutics Inc. stock price move sharplyRecord-setting profit potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Dyne Therapeutics Inc. in the next 12 monthsGet insider insights into market trends - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What is the dividend policy of Dyne Therapeutics Inc. stockFind the best stocks for sustainable growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are the technical indicators suggesting about Dyne Therapeutics Inc.Track emerging stocks with high growth potential - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - ETX View

Jul 27, 2025
pulisher
Jul 24, 2025

Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 21, 2025

Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 18, 2025

Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat

Jul 18, 2025
pulisher
Jul 16, 2025

Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan

Jul 16, 2025
pulisher
Jul 16, 2025

Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

DYN CEO Makes Significant Stock Purchase, Shares Rise | DYN Stoc - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com

Jul 15, 2025

Dyne Therapeutics Inc Stock (DYN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.09
price down icon 1.32%
$37.06
price up icon 1.06%
$101.75
price down icon 2.12%
$27.45
price down icon 4.26%
$112.79
price down icon 2.19%
biotechnology ONC
$294.51
price up icon 1.04%
Cap:     |  Volume (24h):